Basal Insulin Case 2

CE / CME

The Role of Basal Insulin in the Modern Era of Diabetes Management: Interactive Case Challenge 2

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: October 26, 2023

Expiration: October 25, 2024

Activity

Progress
1 2
Course Completed

References

  1. ElSayed NA, Aleppo G, Aroda VR, et al; on behalf of the American Diabetes Association, 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023. Diabetes Care. 2023; 46(suppl 1): S140-S157.
  2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925-1966. 
  3. Human NPH insulin [prescribing information]. Indianapolis, IN: Eli Lilly and Co; 2022.
  4. Insulin detemir [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2022.
  5. Insulin glargine U-100 [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2018. 
  6. Insulin glargine U-300 [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2022.
  7. Insulin degludec U-100 and U-200 [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2022. 
  8. PDR by ConnectiveRx. Lantus SoloStar. www.pdr.net/drug-summary/?drugLabelId=520. Accessed October 3, 2023.
  9. Melo KFS, Bahia LR, Pasinato B, et al. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019;11:2.  
  10. Heinemann L, Parkin CG. Rethinking the viability and utility of inhaled insulin in clinical practice. J Diabetes Res. 2018;2018:4568903.
  11. Edelman SV, Henry RR. Diagnosis and Management of Type 2 Diabetes. 14th edition. Professional Communications; 2022.
  12. Chun J, Strong J, Urquhart S. Insulin initiation and titration in patients with type 2 diabetes. Diabetes Spectr. 2019;32:104-111.
  13. Riddle MC, Bolli GB, Ziemen M, et al; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755-2762.
  14. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23:736-742.
  15. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018;42(suppl 1):S1-S325.
  16. Cowart K. Overbasalization: addressing hesitancy in treatment intensification beyond basal insulin. Clin Diabetes. 2020;38:304-310.